Entries by CURC

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

/0 Comments/in /by

Andrew J. Armstrong, MD, ScM; Russell Z. Szmulewitz, MD; Daniel P. Petrylak, MD; Jeffrey Holzbeierlein, MD; Arnauld Villers, MD; Arun Azad, MBBS, PhD; Antonio Alcaraz, MD, PhD; Boris Alekseev, MD; Taro Iguchi, MD, PhD; Neal D. Shore, MD; Brad Rosbrook, MS; Jennifer Sugg, MS; Benoit Baron, MS; Lucy Chen, MD; and Arnulf Stenzl, MD Click […]

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide

/0 Comments/in /by

Full Title: Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial Neal Shore, Christian Zurth, Robert Fricke, Hille Gieschen, Kristina Graudenz, Mikko Koskinen, Bart Ploeger, Jonathan Moss, Olaf Prien, Gustavo Borghesi, Oana Petrenciuc, Teuvo L. Tammela, Iris Kuss, Frank Verholen, Matthew R. Smith, Karim Fizazi Click here to read more.

Real-World Outcomes of Sipuleucel-T Treatment in PROCEED, a Prospective Registry of Men With Metastatic Castration-Resistant Prostate Cancer

/0 Comments/in /by

Celestia S. Higano, MD1; Andrew J. Armstrong, MD, ScM2,3; A. Oliver Sartor, MD4; Nicholas J. Vogelzang, MD5; Philip W. Kantoff, MD6; David G. McLeod, MD, JD7; Christopher M. Pieczonka, MD8; David F. Penson, MD, MPH9,10; Neal D. Shore, MD11; Jeffrey Vacirca, MD12; Raoul S. Concepcion, MD13; Ronald F. Tutrone, MD14; Luke T. Nordquist, MD15; David […]

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

/in /by

Karim Fizazi, M.D., Neal Shore, M.D., Teuvo L. Tammela, M.D., Ph.D., Albertas Ulys, M.D., Egils Vjaters, M.D., Sergey Polyakov, M.D., Mindaugas Jievaltas, M.D., Murilo Luz, M.D., Boris Alekseev, M.D., Iris Kuss, M.D., Christian Kappeler, Ph.D., Amir Snapir, M.D., Ph.D., Toni Sarapohja, M.Sc., and Matthew R. Smith, M.D., Ph.D. for the ARAMIS Investigators* Background- Darolutamide is […]

Managing Nonmetastatic Castration-resistant Prostate Cancer

/in /by

Joaquin Mateo, Karim Fizazi, Silke Gillessen, Axel Heidenreich, Raquel Perez-Lopez, Wim J.G. Oyen, Neal Shore, Matthew Smith, Christopher Sweeney, Bertrand Tombal, Scott A. Tomlins, Johann S. de Bono. Correspondence information about the author Johann S. de Bono Associate Editor: Giacomo Novara Context Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and […]

A New Sustained-Release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer

/in /by

Neal D.Shore, MD, SílviaGuerrero, PhD, Rosa MaSanahuja, MS, GemmaGambús, MD, PhD, AntonioParente, Ph Purpose This clinical trial investigated the effectiveness, pharmacokinetic properties, and safety profile of leuprolide acetate 22.5-mg depot, a new 3-month leuprolide depot formulation, as androgen deprivation therapy for patients with prostate cancer. click here to read more…